XLO (Xilio Therapeutics, Inc. Common Stock) Stock Analysis - Politician Trades
Xilio Therapeutics, Inc. Common Stock (XLO) is a publicly traded Healthcare sector company. As of May 21, 2026, XLO trades at $8.44 with a market cap of $48.76M and a P/E ratio of -1.97. XLO moved +1.83% today. Year to date, XLO is -10.87%; over the trailing twelve months it is -32.88%. Its 52-week range spans $6.47 to $23.80. Rallies surfaces XLO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded XLO stock?
Rallies tracks politician and congressional stock disclosures for XLO, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Shannon James Samuel bought 5.00K (~$43.95K) on Mar 26, 2026.
Brennan Kevin M. sold 1.83K (~$1.17K) on Jan 2, 2026.
Frankenfield Christopher James sold 7.03K (~$4.52K) on Jan 2, 2026.
XLO Analyst Consensus
XLO analyst coverage data. Average price target: $0.00.
Common questions about XLO
Which politicians traded XLO stock?
Rallies tracks politician and congressional stock disclosures for XLO, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in XLO?
Yes. Rallies tracks politician and congressional stock disclosures for XLO, including reported purchases, sales, dates, owners, and trade amounts when available.
Is XLO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for XLO. It does not provide personalized investment advice.